Marinus Pharmaceuticals' Phase 3 RAISE trial for IV ganaxolone in refractory status epilepticus met rapid cessation endpoint but not anesthesia progression.
Marinus Pharmaceuticals announced mixed results from its Phase 3 RAISE trial evaluating IV ganaxolone for refractory status epilepticus (RSE). The trial met its first co-primary endpoint, showing rapid cessation of status epilepticus, but failed to reach statistical significance in the proportion of patients not progressing to IV anesthesia. The company will continue to analyze the full dataset and discuss with the U.S. FDA.
June 17, 2024
5 Articles